Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D

Oragenics Inc. (NYSE American: OGEN), a biotechnology firm specializing in intranasal pharmaceuticals for neurological disorders, has announced a significant financial move to bolster its research and development activities. The company has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, with each unit priced at $25.00. This strategic offering could generate gross proceeds of up to $20 million, earmarked for advancing the ONP-2 concussion trials, supporting ongoing R&D initiatives, repaying a $3 million bridge note, and covering general corporate expenses.

The Warrants included in the offering grant the holder the right to purchase an additional Preferred share at the same $25.00 price, with the Preferred shares being convertible into common stock at $2.50 per share. Dawson James Securities, Inc. serves as the sole placement agent for this transaction, which is anticipated to close on or about July 2, 2025. This financial infusion is pivotal for Oragenics as it seeks to make strides in the treatment of mild traumatic brain injury (mTBI), commonly known as concussion, and other neurological conditions through its innovative nasal delivery pharmaceuticals.

For further details on this announcement, interested parties can view the full press release here. This development underscores Oragenics' commitment to addressing unmet medical needs in neurology and infectious diseases through its proprietary technologies and drug candidates.